194 related articles for article (PubMed ID: 36048313)
1. Incidence and predictors of recurrent sick leave in survivors who returned to work after allogeneic hematopoietic cell transplantation.
Kurosawa S; Yamaguchi T; Mori A; Matsuura T; Masuko M; Murata M; Tashiro H; Kako S; Satake A; Hagihara M; Ota S; Saito T; Kagawa K; Matsuo Y; Itonaga H; Uoshima N; Yamaguchi H; Naito K; Takahashi M; Fukuda T
J Cancer Surviv; 2023 Jun; 17(3):781-794. PubMed ID: 36048313
[TBL] [Abstract][Full Text] [Related]
2. Resignation and return to work in patients receiving allogeneic hematopoietic cell transplantation close up.
Kurosawa S; Yamaguchi T; Mori A; Matsuura T; Mori T; Tanaka M; Kondo T; Umemoto Y; Goto H; Yoshioka S; Machida S; Sato T; Katayama Y; Kato S; Shono K; Mizuno I; Fujiwara SI; Kohno A; Takahashi M; Fukuda T
J Cancer Surviv; 2022 Oct; 16(5):1004-1015. PubMed ID: 34449050
[TBL] [Abstract][Full Text] [Related]
3. Recurrent sick leave and resignation rates among female cancer survivors after return to work: the Japan sickness absence and return to work (J-SAR) study.
Endo M; Haruyama Y; Muto G; Imai Y; Mitsui K; Mizoue T; Wada H; Kobashi G; Tanigawa T
BMC Public Health; 2019 Sep; 19(1):1248. PubMed ID: 31510964
[TBL] [Abstract][Full Text] [Related]
4. Important factors associated with sick leave after allogeneic haematopoietic stem cell transplantation-a 1-year prospective study.
Eriksson L; Wennman-Larsen A; Bergkvist K; Ljungman P; Winterling J
J Cancer Surviv; 2021 Dec; 15(6):933-941. PubMed ID: 33417181
[TBL] [Abstract][Full Text] [Related]
5. Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States.
Bhatt NS; Brazauskas R; Salit RB; Syrjala K; Bo-Subait S; Tecca H; Badawy SM; Baker KS; Beitinjaneh A; Bejanyan N; Byrne M; Dias A; Farhadfar N; Freytes CO; Ganguly S; Hashmi S; Hayashi RJ; Hong S; Inamoto Y; Jamani K; Kasow KA; Khera N; Krem MM; Lazarus HM; Lee CJ; Lee S; Majhail NS; Malone AK; Marks DI; Mau LW; Mayo SJ; Muffly LS; Nathan S; Nishihori T; Page KM; Preussler J; Rangarajan HG; Rotz SJ; Salooja N; Savani BN; Schears R; Schechter-Finkelstein T; Schiller G; Shah AJ; Sharma A; Wang T; Wirk B; Battiwalla M; Schoemans H; Hamilton B; Buchbinder D; Phelan R; Shaw B
Transplant Cell Ther; 2021 Aug; 27(8):679.e1-679.e8. PubMed ID: 33895402
[TBL] [Abstract][Full Text] [Related]
6. Occupational status among adult survivors following allogeneic stem cell transplantation in childhood.
Winterling J; Johansson E; Wettergren L; Ljungman P; Alexanderson K
Eur J Cancer Care (Engl); 2018 Mar; 27(2):e12808. PubMed ID: 29315926
[TBL] [Abstract][Full Text] [Related]
7. Returning to work after sick leave due to cancer: a 365-day cohort study of Japanese cancer survivors.
Endo M; Haruyama Y; Takahashi M; Nishiura C; Kojimahara N; Yamaguchi N
J Cancer Surviv; 2016 Apr; 10(2):320-9. PubMed ID: 26318185
[TBL] [Abstract][Full Text] [Related]
8. Employment sustainability after return to work among Japanese stroke survivors.
Endo M; Haruyama Y; Muto G; Yokoyama K; Kojimahara N; Yamaguchi N
Int Arch Occup Environ Health; 2018 Aug; 91(6):717-724. PubMed ID: 29802486
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and Determinants of Return to Work as a Patient-Centered Outcome in Survivors of Hematopoietic Cell Transplantation.
Bhatt NS
Curr Hematol Malig Rep; 2022 Dec; 17(6):228-242. PubMed ID: 36194316
[TBL] [Abstract][Full Text] [Related]
10. Returning to Work Following Hematopoietic Cell Transplantation: The Survivor's Perspective.
Salit RB; Lee SJ; Bhatt NS; Carpenter PA; Fan X; Armstrong A; Oshima MU; Connelly-Smith L; Krakow E; Lee CJ; Vo P; Mehta R; Syrjala KL
Transplant Cell Ther; 2024 Jun; 30(6):612.e1-612.e12. PubMed ID: 38561139
[TBL] [Abstract][Full Text] [Related]
11. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
Klyuchnikov E; Bacher U; Kröger NM; Hari PN; Ahn KW; Carreras J; Bachanova V; Bashey A; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Hertzberg MS; Holmberg LA; Kharfan-Dabaja MA; Klein A; Ku GH; Laport GG; Lazarus HM; Miller AM; Mussetti A; Olsson RF; Slavin S; Usmani SZ; Vij R; Wood WA; Maloney DG; Sureda AM; Smith SM; Hamadani M
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2091-2099. PubMed ID: 26253007
[TBL] [Abstract][Full Text] [Related]
12. Return-to-Work Guidelines and Programs for Post-Hematopoietic Cell Transplantation Survivors: An Initial Survey.
Salit RB; Lee SJ; Burns LJ; Shaw BE; Majhail NS; Bhatt NS; Wood WA; Syrjala KL
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1520-1526. PubMed ID: 32360563
[TBL] [Abstract][Full Text] [Related]
13. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma.
Afrough A; Alsfeld LC; Milton DR; Delgado R; Popat UR; Nieto Y; Kebriaei P; Oran B; Saini N; Srour S; Hosing C; Cheema FH; Ahmed S; Manasanch EE; Lee HC; Kaufman GP; Patel KK; Weber DM; Orlowski RZ; Pinnix CC; Dabaja BS; Thomas SK; Champlin RE; Shpall EJ; Qazilbash MH; Bashir Q
Transplant Cell Ther; 2023 Apr; 29(4):264.e1-264.e9. PubMed ID: 35605883
[TBL] [Abstract][Full Text] [Related]
15. Return to Work in Survivors of Human Papillomavirus-Associated Oropharyngeal Cancer: An Australian Experience.
Morales CZ; McDowell L; Lisy K; Piper A; Jefford M
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):146-156. PubMed ID: 31521718
[TBL] [Abstract][Full Text] [Related]
16. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.
Orti G; Sanz J; Bermudez A; Caballero D; Martinez C; Sierra J; Cabrera Marin JR; Espigado I; Solano C; Ferrà C; García-Noblejas A; Jimenez S; Sampol A; Yañez L; García-Gutiérrez V; Pascual MJ; Jurado M; Moraleda JM; Valcarcel D; Sanz MA; Carreras E; Duarte RF
Biol Blood Marrow Transplant; 2016 Mar; 22(3):584-8. PubMed ID: 26631751
[TBL] [Abstract][Full Text] [Related]
17. Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma.
Syrjala KL; Langer SL; Abrams JR; Storer B; Sanders JE; Flowers ME; Martin PJ
JAMA; 2004 May; 291(19):2335-43. PubMed ID: 15150205
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.
Kharfan-Dabaja M; Mhaskar R; Reljic T; Pidala J; Perkins JB; Djulbegovic B; Kumar A
Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010280. PubMed ID: 25061777
[TBL] [Abstract][Full Text] [Related]
19. Late-occurring infections in a contemporary cohort of hematopoietic cell transplantation survivors.
Sy A; Chanson D; Berano Teh J; Wong FL; Nakamura R; Dadwal S; Armenian SH
Cancer Med; 2021 May; 10(9):2956-2966. PubMed ID: 33835722
[TBL] [Abstract][Full Text] [Related]
20. Return to paid work after cancer: a British experience.
Amir Z; Moran T; Walsh L; Iddenden R; Luker K
J Cancer Surviv; 2007 Jun; 1(2):129-36. PubMed ID: 18648953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
